Antiepileptic drugs and reduced bone mineral density

Epilepsy and Behavior

Volumn 5, Issue 3, 2004, Pages 296-300

  Ali, Imran I ^a   Schuh, Lori ^b   Barkley, Gregory L ^b   Gates, John R ^c  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b HENRY FORD HOSPITAL   (United States)

^c MINNESOTA EPILEPSY GROUP   (United States)

Author keywords

Antiepileptic drugs; Bone mineral density; Bone turnover; Osteopenia; Osteoporosis

Indexed keywords

ALENDRONIC ACID; ANTICONVULSIVE AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CARBAMAZEPINE; PARATHYROID HORMONE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; VALPROIC ACID; VITAMIN D;

BLEEDING; BONE DENSITY; BONE MINERAL; DUAL ENERGY X RAY ABSORPTIOMETRY; EPILEPSY; ESOPHAGUS STRICTURE; FRAGILITY FRACTURE; HUMAN; KIDNEY FAILURE; MEDICAL LITERATURE; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; REVIEW; BONE DISEASE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; METHODOLOGY; RADIODENSITOMETRY;

ANTICONVULSANTS; BONE DENSITY; BONE DISEASES; DENSITOMETRY, X-RAY; EPILEPSY; HUMANS;

EID: 3042663663     PISSN: 15255050     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yebeh.2004.02.005     Document Type: Review

References (60)

1. Hahn T.J. Hendin B.A. Scharp C.R. Haddad J.G. Effect of chronic anticonvulsant therapy on serum 25-hydroxycalciferol levels in adults N. Engl. J. Med. 1972 900-904
2. Hahn T.J. Birge S.J. Scharp C.R. Avioli L.V. Phenobarbital-induced alterations in vitamin D metabolism J. Clin. Invest. 51 1972 741-748
3. Hunter J. Maxwell J.D. Stewart D.A. Parsons V. Williams R. Altered calcium metabolism in epileptic children on anticonvulsants Br. Med. J. 4 1971 202-204
4. Winnacker J.L. Yeager H. Saunders J.A. Russell B. Anast C.S. Rickets in children receiving anticonvulsant drugs Am. J. Dis. Child. 131 1977 286-290
5. Hahn T.J. Hendin B.A. Scharp C.R. Boisseau V.C. Haddad J.G. Serum 25-hydroxycalciferol levels and bone mass in children on chronic anticonvulsant therapy N. Engl. J. Med. 292 1975 550-554
6. Farhat G. Yamout B. Mikati M.A. Demirijan S. Sawaya R. Fuleihan G.E. Effect of antiepileptic drugs on bone density in ambulatory patients Neurology 58 2002 1348-1353
7. Hoikka V. Alhava E. Karjalainen P. et al. Carbamazepine and bone mineral metabolism Acta Neurol. Scand. 69 1984 77-80
8. Hoikka V. Savolainen K. Alhava E.M. Sivenius J. Karjalainen P. Repo A. Osteomalacia in institutionalized epileptic patients on long-term therapy Acta Neurol. Scand. 64 1981 122-131
9. Valmadrid C. Voorhes C. Litt B. Schneyer C.R. Practice patterns of neurologists regarding bone and mineral effects of antiepileptic drug therapy Arch. Neurol. 58 2001 1369-1374
10. Takeshita N. Seino Y. Ishida H. et al. Increased circulating levels of gamma-carboxyglutamic acid-containing protein and decreased bone mass in children on anticonvulsant therapy Calcif. Tissue Int. 44 1989 80-85
11. Telci A. Cakatay U. Kurt B.B. et al. Changes in bone turnover and deoxypryidinoline levels in epileptic patients Clin. Chem. Lab. Med. 38 2000 47-50
12. Timperlake R.W. Cook S.D. Thomas K.A. et al. Effects of anticonvulsant drug therapy on bone mineral density in a pediatric population J. Pediat. Orthop. 8 1988 467-470
13. Valimaki M. Tiihonen M. Latinen K. et al. Bone mineral density measured by dual energy X-ray absorptiometry and novel markers of bone formation and resorption in patients on antiepileptic drugs J. Bone Miner. Res. 9 1994 631-637
14. Kubota F. Kifune A. Shibata N. et al. Bone mineral density of epileptic patients on long term antiepileptic therapy: a quantitative digital radiographic study Epilepsy Res. 33 1999 93-97
15. Barden H.S. Mazess R.B. Rose P.G. McAweeney W. Bone mineral status measured by direct photon absorptiometry in institutionalized adults receiving long-term anticonvulsant therapy and multivitamin supplementation Calcif. Tissue Int. 31 1980 117-121
16. Lamberg-Allardt C. Wilska M. Saraster K.L. Gronlund T. Vitamin D status of ambulatory and nonambulatory mentally retarded children with and without carbamazepine treatment Ann. Nutr. Metab. 34 1990 216-220
17. Bouillon R. Reynaert J. Claes J.H. Lissens W. DeMoor P. The effect of anticonvulsant therapy on serum levels of 25-hydroxyvitamin D, calcium and parathyroid hormone J. Clin. Endocrinol. Metab. 41 1975 1130-1135
18. Gough H. Goggin G. Bissessar A. Baker M. Crowley M. Callaghan N. A comparative study of the relative influence of different anticonvulsant drugs, UV exposure and diet on vitamin D and calcium metabolism in outpatients with epilepsy Q. J. Med. 230 1986 569-577
19. Guo C.Y. Ronen G. Atkinson S. Long term valproate and lamotrigine treatment may be a marker for reduced growth and bone mass in children with epilepsy Epilepsia 42 2001 1141-1147
20. Christiansen C. Rodbro P. Lund M. Incidence of anticonvulsant osteomalacia and effect of vitamin D: controlled therapeutic trial Br. Med. J. 4 1973 695-701
21. Tjellesen L. Christiansen C. Serum vitamin D metabolites in epileptic patients treated with 2 different anti-convulsants Acta Neurol. Scand. 66 1982 335-341
22. Tjellesen L. Nilas L. Christiansen C. Does carbamazepine cause disturbances in calcium metabolism in epileptic patients? Acta Neurol. Scand. 68 1983 13-19
23. Koch H.C. Kraft D. von Herrath D. Influence of diphenylhydantoin and phenobarbital on intestinal calcium transport in the rat Epilepsia 13 1972 829-841
24. Weinstein R. Bryce G. Sappington L.J. King D.W. Gallagher B.B. Decreased serum ionized calcium and normal vitamin D metabolite levels in patients with anticonvulsant drug treatment J. Clin. Endocrinol. Metab. 58 1984 1003-1009
25. Zerwekh J. Homan R. Tindall R. Pak C.Y. Decreased serum 24, 25-dihydroxyvitamin D concentration during long-term anticonvulsant therapy in adult epileptics Ann. Neurol. 12 1982 184-186
26. Mosedike L. Melsen F. Dynamic differences in trabecular bone remodeling between patients after jejuno-ileal bypass for obesity and epileptic patients receiving anticonvulsant therapy Metab. Bone Dis. Relat. Res. 2 1980 77-82
27. ′-cyclic monophosphate production Calcif. Tissue Res. 16 1974 163-167
28. 2 (menatetrenone) on bone mineral density of growing rats Life Sci. 70 2002 1533-1542
29. Onedera K. Takahashi A. Mayanagi H. Wakabayashi H. Kamei J. Shinoda H. Phenytoin induced bone loss and it prevention with alfacalcidol and calcitriol in growing rats Calcif. Tissue Int. 69 2001 109-116
30. Lifshitz F. Maclaren N.K. Vitamin D-dependent rickets in institutionalized, mentally retarded children receiving long-term anticonvulsant therapy: I. A survey of 288 patients J. Pediatr. 83 1973 612-620
31. Verotti A. Greco R. Morgese G. Chiarelli F. Increased bone turnover in epileptic patients treated with carbamazepine Ann. Neurol. 47 2000 385-388
32. Feldkamp J. Becker A. Wilte O.W. Scharff D. Scherbaum W.A. Long-term anticonvulsant therapy leads to low bone mineral density: evidence for direct drug effects of phenytoin and carbamazepine on human osteoblast-like cells Exp. Clin. Endocrinol. Diabetes 108 2000 37-43
33. Hahn T.J. Scharp C.R. Richardson C.A. Halstead L.R. Kahn A.J. Teitelbaum S.L. Interaction of diphenylhydantoin and phenobarbital with hormonal mediation of fetal rat bone resorption in vitro J. Clin. Invest. 62 1978 406-414
34. Stephen L.J. McLellan A.R. Harrison J.H. et al. Bone density and antiepileptic drugs: a case controlled study Seizure 8 1999 339-342
35. Sheth R. Wesolewski C.A. Jacob J.C. et al. Effect of carbamazepine and valproate on bone mineral density J. Pediatr. 127 1995 256-262
36. Akin R. Okutan V. Sarici U. Evaluation of bone mineral density in children receiving antiepileptic drugs Pediatr. Neurol. 19 1998 129-131
37. Pluskiewicz W. Nowakowska J. Bone status after long-term anticonvulsant therapy in epileptic patients: evaluation using quantitative ultrasound of calcaneus and phalanges Ultrasound Med. Biol. 23 1997 553-558
38. Chung S. Ahn C. Effects of anti-epileptic drug therapy on bone mineral density in ambulatory epileptic children Brain Dev. 16 1994 382-385
39. Vestergaard P. Tigaran S. Rejnmork L. Tigaran C. Dam M. Mosekilde L. Fracture risk is increased in epilepsy Acta Neurol. Scand. 99 1999 269-275
40. Pavlaikis S. Chusid R. Roye D.P. Nordli D.R. Valproate therapy: predisposition to bone fracture? Pediatr. Neurol. 19 1998 143-144
41. 3 administration Calcif. Tissue Int. 27 1979 12-18
42. Collins N. Maher J. Cole M. Baker M. Callaghan N. A prospective study to evaluate the dose of vitamin D required to correct low 25-hydroxyvitamin D levels, calcium, and alkaline phosphatase in patients at risk of developing antiepileptic drug induced osteomalacia Q. J. Med. 286 1991 113-122
43. Silver J. Davies T.J. Kupersmitt E. Orme M. Petrie A. Vajda F. Prevalence and treatment of vitamin D deficiency in children on anticonvulsant drugs Arch. Dis. Child. 49 1974 344-349
44. Jekovec-Vrhosek M. Kocijancic A. Prezelj J. Effect of vitamin D and calcium on bone mineral density in children with CP and epilepsy in full time care Dev. Med. Child Neurol. 42 2000 403-405
45. Morijiri Y. Sato J. Factors causing rickets in institutionalized handicapped children on anticonvulsant therapy Arch. Dis. Child 56 1981 446-449
46. Murchison L.E. Bewsher P.D. Chesters M. et al. Effects of anticonvulsants and inactivity on bone disease in epileptics Postgrad. Med. J. 51 1975 18-21
47. Tolman K.G. Jubiz W. Sannella J.J. et al. Osteomalacia associated with anticonvulsant drug therapy in mentally retarded children Pediatrics 56 1975 45-51
48. Fischer M. Adkins W. Liebl B. VanCalcar S. Marlett J. Bone status in nonambulant, epileptic institutionalized youth Clin. Pediatr. 27 1988 499-505
49. Davie M.W. Emberson C.E. Lawson D.E. et al. Low plasma 25-hydroxyvitamin D and serum calcium levels in institutionalized epileptic subjects: associated risk factors, consequences and response to treatment with vitamin D Q. J. Med. 205 1983 79-91
50. Ala-Houhala M. Korpela R. Koivikko M. Long term anticonvulsant therapy and vitamin D metabolism in ambulatory pubertal children Neuropediatrics 17 1986 212-216
51. Erbayat A.E. Serdaroglu A.T.L. Gucuyener K. Hasanoglu A. Evaluation of bone mineral metabolism in children receiving carbamazepine and valproic acid J. Pediatr. Endocrinol. Metab. 13 2000 933-939
52. Karaaslan Y. Haznedagorlou S. Osturk M. Osteomalacia associated with carbamazepine/valproate Ann. Pharmacol. 34 2000 264-265
53. Livingston S. Berman W. Pauli L. Anticonvulsant drugs and vitamin D metabolism JAMA 224 1973 1034-1035
54. Sato Y. Kondo I. Ishida S. et al. Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy Neurology 57 2001 445-449
55. Andresss D.L. Ozuna J. Tirschwell D. et al. Antiepileptic drug-induced bone loss in young male patients who have seizures Arch. Neurol. 59 2002 781-786
56. Baer M. Kozlowski B. Blyler E.M. Trahms C.M. Taylor M.L. Hogan M.P. Vitamin D, calcium, and bone status in children with developmental delay in relation to anticonvulsant use and ambulatory status Am. J. Clin. Nutr. 65 1997 1042-1051
57. 3 on bone mineral content in carbamazepine treated epileptic patients Acta Neurol. Scand. 68 1983 424-428
58. Drezner M.K. Treatment of anticonvulsant drug-induced bone disease Epilepsy Behav. 5 Suppl 2 2004 41-47
59. Pack A. Morrell M.J. Epilepsy and bone health in adults Epilepsy Behav. 5 Suppl 2 2004 24-29
60. Fitzpatrick L.A. Pathophysiology of bone loss in patients receiving anticonvulsant therapy Epilepsy Behav. 5 Suppl 2 2004 3-15